Premenstrual Symptoms Screening Tool
Premenstrual Symptoms Screening Tool (PSST) · Also known as: PSST, Premenstrual Symptom Screening
The Premenstrual Symptoms Screening Tool (PSST) is a brief, 19-item self-report questionnaire designed to screen for premenstrual dysphoric disorder (PMDD) and assess the severity of premenstrual symptoms. Developed by Steiner, Macdougall, and Brown in 2003, the PSST efficiently identifies women with clinically significant cyclical mood and physical symptoms warranting diagnostic evaluation and potential pharmacological or psychological treatment.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The PSST is appropriate for screening in gynecologic clinics, primary care, and mental health settings when women report cyclical mood or behavioral changes. It is particularly valuable in women with treatment-resistant depression or anxiety that may have a premenstrual cyclical component. The scale helps clinicians distinguish PMDD (a discrete cyclical disorder) from chronic depression, anxiety, or personality disorders. It is also useful for monitoring symptom response to PMDD treatments (SSRIs, hormonal contraceptives, lifestyle modifications) across menstrual cycles.
Strengths & limitations
- Brief and efficient (3-5 minutes), facilitating integration into busy clinical encounters.
- Assesses both affective and somatic premenstrual symptoms, enabling comprehensive symptom profiling.
- Specifically designed to capture cycle-dependent symptomatology; items reference premenstrual timing, enhancing diagnostic relevance.
- Validated against DSM-5 PMDD diagnostic criteria; demonstrates good sensitivity and specificity for PMDD detection.
- Free to use in clinical and research settings without licensing fees.
- Not a diagnostic instrument; high scores require clinical interview and structured DSM-5 diagnostic assessment.
- Relies on retrospective recall of premenstrual symptoms; prospective symptom tracking (daily charting over 2-3 cycles) is more reliable for confirming cyclical pattern.
- Does not differentiate PMDD from severe premenstrual syndrome (PMS); both score elevated, though PMDD carries greater functional impairment.
- May be less reliable in women with irregular menstrual cycles or anovulatory cycles where premenstrual phase is not well-defined.
Frequently asked
Is premenstrual syndrome (PMS) the same as PMDD?
No. PMS is common (affects 30-50% of menstruating women) and includes mild to moderate cyclical physical or mood symptoms. PMDD is a more severe condition affecting 5-8% of menstruating women, characterized by significant mood, anxiety, or behavioral symptoms causing substantial functional impairment. PMDD requires DSM-5 diagnostic criteria; PMS does not. Both score elevated on PSST, but PMDD carries greater severity and impairment.
Can I self-diagnose PMDD using the PSST?
The PSST can raise suspicion for PMDD if scores are ≥20, but it cannot diagnose PMDD. Diagnosis requires clinical evaluation by a healthcare provider, confirmation of cyclical symptomatology via prospective symptom tracking, and exclusion of other explanations. Self-assessment is a starting point; professional evaluation is necessary.
When should I complete the PSST?
Complete the PSST by rating your worst symptoms during the luteal phase—specifically the 5-7 days before menstruation starts. Do not rate baseline or follicular-phase experience. Timing is crucial for accurate screening. Ideally, complete the PSST after at least 2 menstrual cycles of prospective tracking.
What treatments are available for PMDD?
Evidence-based PMDD treatments include: SSRIs (sertraline, fluoxetine, paroxetine, approved by FDA specifically for PMDD), hormone-containing contraceptives (especially those with extended or continuous dosing), GnRH agonists (for severe refractory PMDD), and psychosocial interventions (cognitive-behavioral therapy, mindfulness, lifestyle modifications including aerobic exercise, dietary calcium). Treatment choice depends on symptom severity, contraceptive needs, and individual preference.
Sources
- Steiner, M., Macdougall, M., & Brown, E. (2003). The Premenstrual Symptoms Screening Tool (PSST) for clinicians. Archives of Women's Mental Health, 6(3), 203-209. DOI: 10.1007/s00737-003-0018-4 ↗
- Steiner, M., & Born, L. (2000). Diagnosis and treatment of premenstrual dysphoric disorder: an update. CNS Drug Reviews, 6(1), 5-17. link ↗
How to cite this page
ScholarGate. (2026, June 3). Premenstrual Symptoms Screening Tool (PSST). ScholarGate. https://scholargate.app/en/obstetrics-gynecology/premenstrual-symptoms-screening
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Female Pelvic Pain ScaleObstetrics Gynecology↔ compare
- Menopause-Specific Quality of Life QuestionnaireObstetrics Gynecology↔ compare
- Perinatal Anxiety Screening ScaleObstetrics Gynecology↔ compare